These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23672493)

  • 1. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
    Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
    BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
    FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
    Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
    Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.
    Hayashi N; Kataoka H; Yano S; Kikuchi JI; Tanaka M; Nishie H; Kinoshita Y; Hatano M; Nomoto A; Ogawa A; Inoue M; Mizoshita T; Shimura T; Mori Y; Kubota E; Tanida S; Joh T
    Anticancer Res; 2016 Nov; 36(11):6005-6009. PubMed ID: 27793927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
    Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.
    Maeda S; Sugiura T; Saikawa Y; Kubota T; Otani Y; Kumai K; Kitajima M
    Cancer Sci; 2004 Aug; 95(8):679-84. PubMed ID: 15298732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
    Geng M; Wang L; Chen X; Cao R; Li P
    Diagn Pathol; 2013 Dec; 8():198. PubMed ID: 24326092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
    Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
    Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
    Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
    Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.
    Xia Y; Yang W; Bu W; Ji H; Zhao X; Zheng Y; Lin X; Li Y; Lu Z
    J Biol Chem; 2013 Jul; 288(27):19321-9. PubMed ID: 23678002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
    Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.
    Cao X; Li R; Xiong H; Su J; Guo C; An T; Zong H; Zhao R
    Eur J Med Chem; 2021 Oct; 221():113520. PubMed ID: 34029775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer.
    Yu HE; Wang F; Yu F; Zeng ZL; Wang Y; Lu YX; Jin Y; Wang DS; Qiu MZ; Pu HY; Kang TB; Xie D; Ju HQ; Xu RH; Luo HY
    Cell Death Dis; 2019 May; 10(6):413. PubMed ID: 31138787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.
    Song C; Duan C
    Med Sci Monit; 2020 May; 26():e921002. PubMed ID: 32442162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
    Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
    J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
    Li R; Zhao W; Jin C; Xiong H
    Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.